Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06713499Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Dec 2024; status: completed.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06713499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713499.